Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany.
Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany; Paul Langerhans Institute Dresden (PLID), Helmholtz Center Munich, University Hospital and Faculty of Medicine, TU Dresden, Fetscherstraße 74, 01307 Dresden, Germany; German Center for Diabetes Research (DZD e.V.), IngolstädterLandstrasse 1, 85764 Neuherberg, Germany.
Diabetes Res Clin Pract. 2023 May;199:110636. doi: 10.1016/j.diabres.2023.110636. Epub 2023 Mar 20.
We aimed to compare the concentrations of GLP-1, glucagon and GIP (established regulators of glucose homeostasis) and glicentin (emerging new metabolic marker)during an OGTT in patients with normal glucose tolerance (NGT), prediabetes and diabetes at onset, and one-year before, when all had prediabetes.
GLP-1, glucagon, GIP and glicentin concentrations were measured and compared with markers of body composition, insulin sensitivity and β-cell function at a 5-timepoint OGTT in 125 subjects (30 diabetes, 65 prediabetes, 30 NGT) and in 106 of them one-year before, when all had prediabetes.
At baseline, when all subjects were in prediabetic state, hormonal levels did not differ between groups. One year later, patients progressing to diabetes had lower postprandial increases of glicentin and GLP-1, lower postprandial decrease of glucagon, and higher levels of fasting GIP compared to patients regressing to NGT. Changes in glicentin and GLP-1 AUC within this year correlated negatively with changes in Glucose AUC of OGTT and with changes in markers of beta cell function.
Incretins, glucagon and glicentin profiles in prediabetic state cannot predict future glycemic traits, but prediabetes progressing to diabetes is accompanied by deterioration of postprandial increases of GLP-1 and glicentin.
我们旨在比较葡萄糖耐量正常(NGT)、糖尿病前期和发病时的患者在口服葡萄糖耐量试验(OGTT)期间 GLP-1、胰高血糖素和 GIP(公认的血糖稳态调节剂)以及肠高血糖素(新兴的新代谢标志物)的浓度,并在所有患者均患有糖尿病前期时,比较他们在一年前的浓度。
在 125 名受试者(30 名糖尿病患者、65 名糖尿病前期患者和 30 名 NGT 患者)的 5 个时间点 OGTT 中测量了 GLP-1、胰高血糖素、GIP 和肠高血糖素浓度,并与身体成分、胰岛素敏感性和β细胞功能的标志物进行了比较,其中 106 名受试者在一年前,当时他们均患有糖尿病前期。
在基线时,当所有受试者均处于糖尿病前期状态时,各组之间的激素水平没有差异。一年后,进展为糖尿病的患者的肠高血糖素和 GLP-1 的餐后增加减少,胰高血糖素的餐后下降减少,空腹 GIP 水平升高,与回归为 NGT 的患者相比。在这一年内,肠高血糖素和 GLP-1 AUC 的变化与 OGTT 葡萄糖 AUC 的变化以及β细胞功能标志物的变化呈负相关。
在糖尿病前期状态下,肠高血糖素和 GLP-1 以及胰高血糖素的特征不能预测未来的血糖特征,但进展为糖尿病的糖尿病前期患者的 GLP-1 和肠高血糖素的餐后增加恶化。